The 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV

The Body Covers:

The 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV

Athenaeum Inter-Continental, Athens, Greece

October 23-26, 2001

The Body's Conference Summaries
Other Reports and Articles

Graeme Moyle, M.D.

The International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV is an opportunity for leading clinicians and scientists to discuss abnormalities and side effects associated mainly with highly active antiretroviral therapy (HAART). The conference is organized by the International Medical Press, whose goal is to promote exchanges of information and opinion between members of the scientific and medical communities.

In light of the prevalence of metabolic abnormalities among HIV-positive individuals treated with HAART, this year's conference will seek to help professionals better understand these adverse effects. Scientists and clinicians will also share the latest available therapy information. For more on this conference, visit: conferences.intmedpress.com/lipodystrophy.

Reporting exclusively for The Body at this workshop is Dr. Graeme Moyle.

Funding for The Body's conference coverage is provided, in part, by unrestricted educational grants from Boehringer-Ingelheim, Bristol-Myers Squibb and GlaxoSmithKline.

The Body's Conference Summaries

Different Lactate Metabolism in Patients with and without HIV-Associated Lipodystrophy Syndrome
Increased Rates of Lipolysis Among HIV-Infected Men with and Without Fat Redistribution
Acute Inhibition of Lipolysis Improves Insulin Sensitivity in Patients with HIV Lipodystrophy and Insulin Resistance
Hyperlactatemia and Lactic Acidosis During Antiretroviral Therapy: Relevance, Reproducibility, Possible Risk Factors
Elevated In Vitro Tumor Necrosis Factor a Release from Abdominal Subcutaneous Adipose Tissue (SAT) in HIV-Infected Subjects with Lipodystrophy
Differential In Vitro Effects of Indinavir, Nelfinavir and Amprenavir On Cell Differentiation, Insulin Sensitivity and Apoptosis In an Adapted Adipose Cell Model -- Preventive Impact of Rosiglitazone
Comparison of the Metabolic Disorders and Clinical Lipodystrophy 48 Weeks After Switching from HAART to Trizivir Versus Continued HAART (TRIZAL: AZL30002)
Prospective Study of Hyperlipidemia in ART-Naive Subjects Taking Abacavir/Combivir (ABC/COM), COM/nelfinavir (NFV), or Lamivudine (3TC)/Stavudine (d4T)/NFV (GSK Protocol ESS40002)

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

The Body is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.